|
1
|
Ruzzenente A, Iacono C, Conci S, Bertuzzo
F, Salvagno G, Ruzzenente O, Campagnaro T, Valdegamberi A, Pachera
S, Bagante F and Guglielmi A: A novel serum marker for biliary
tract cancer: Diagnostic and prognostic values of quantitative
evaluation of serum mucin 5AC (MUC5AC). Surgery. 155:633–639. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: Accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu Y and Wu PY: CD133 as a marker for
cancer stem cells: Progresses and concerns. Stem Cells Dev.
18:1127–1134. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Irollo E and Pirozzi G: CD133: To be or
not to be, is this the real question? Am J Transl Res. 5:563–581.
2013.PubMed/NCBI
|
|
5
|
Li Z: CD133: A stem cell biomarker and
beyond. Exp Hematol Oncol. 2:172013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pallini R, Ricci-Vitiani L, Montano N,
Mollinari C, Biffoni M, Cenci T, Pierconti F, Martini M, De Maria R
and Larocca LM: Expression of the stem cell marker CD133 in
recurrent glioblastoma and its value for prognosis. Cancer.
117:162–174. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao P, Lu Y, Jiang X and Li X:
Clinicopathological significance and prognostic value of CD133
expression in triple-negative breast carcinoma. Cancer Sci.
102:1107–1111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu S, Yu L, Wang D, Zhou L, Cheng Z, Chai
D, Ma L and Tao Y: Aberrant expression of CD133 in non-small cell
lung cancer and its relationship to vasculogenic mimicry. BMC
Cancer. 12:5352012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maeda S, Shinchi H, Kurahara H, Mataki Y,
Maemura K, Sato M, Natsugoe S, Aikou T and Takao S: CD133
expression is correlated with lymph node metastasis and vascular
endothelial growth factor-C expression in pancreatic cancer. Br J
Cancer. 98:1389–1397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sasaki A, Kamiyama T, Yokoo H, Nakanishi
K, Kubota K, Haga H, Matsushita M, Ozaki M, Matsuno Y and Todo S:
Cytoplasmic expression of CD133 is an important risk factor for
overall survival in hepatocellular carcinoma. Oncol Rep.
24:537–546. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takahashi S, Kamiyama T, Tomaru U, Ishizu
A, Shida T, Osaka M, Sato Y, Saji Y, Ozaki M and Todo S: Frequency
and pattern of expression of the stem cell marker CD133 have strong
prognostic effect on the surgical outcome of colorectal cancer
patients. Oncol Rep. 24:1201–1212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shimada M, Sugimoto K, Iwahashi S,
Utsunomiya T, Morine Y, Imura S and Ikemoto T: CD133 expression is
a potential prognostic indicator in intrahepatic
cholangiocarcinoma. J Gastroenterol. 45:896–902. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fan L, He F, Liu H, Zhu J, Liu Y, Yin Z,
Wang L, Guo Y, Wang Z, Yan Q and Huang G: CD133: A potential
indicator for differentiation and prognosis of human
cholangiocarcinoma. BMC Cancer. 11:3202011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leelawat K, Thongtawee T, Narong S,
Subwongcharoen S and Treepongkaruna SA: Strong expression of CD133
is associated with increased cholangiocarcinoma progression. World
J Gastroenterol. 17:1192–1198. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hermansen SK, Christensen KG, Jensen SS
and Kristensen BW: Inconsistent immunohistochemical expression
patterns of four different CD133 antibody clones in glioblastoma. J
Histochem Cytochem. 59:391–407. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Croker AK, Goodale D, Chu J, Postenka C,
Hedley BD, Hess DA and Allan AL: High aldehyde dehydrogenase and
expression of cancer stem cell markers selects for breast cancer
cells with enhanced malignant and metastatic ability. J Cell Mol
Med. 13:2236–2252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hashimoto K, Aoyagi K, Isobe T, Kouhuji K
and Shirouzu K: Expression of CD133 in the cytoplasm is associated
with cancer progression and poor prognosis in gastric cancer.
Gastric Cancer. 17:97–106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ferrandina G, Martinelli E, Petrillo M,
Prisco MG, Zannoni G, Sioletic S and Scambia G: CD133 antigen
expression in ovarian cancer. BMC Cancer. 9:2212009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fukamachi H, Shimada S, Ito K, Ito Y and
Yuasa Y: CD133 is a marker of gland-forming cells in gastric tumors
and Sox17 is involved in its regulation. Cancer Sci. 102:1313–1321.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bauer N, Wilsch-Bräuninger M, Karbanová J,
Fonseca AV, Strauss D, Freund D, Thiele C, Huttner WB, Bornhäuser M
and Corbeil D: Haematopoietic stem cell differentiation promotes
the release of prominin-1/CD133-containing membrane vesicles-a role
of the endocytic-exocytic pathway. EMBO Mol Med. 3:398–409. 2011.
View Article : Google Scholar : PubMed/NCBI
|
